# US 2024/0002805 A1 · Optogenetic modulation of action-potential properties

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0002805 A1
- Document ID: US20240002805A1
- Status: Published application
- Kind: A1
- Application number: 18/039,381
- Filed: 2021-11-30
- Published: 2024-01-04
- Earliest claimed: 2020-11-30
- Assignees: Technion Research & Development Foundation Limited; Ramban Medtech Ltd.
- Applicants: Technion Research & Development Foundation Limited; Ramban Medtech Ltd.
- Inventors: Lior GEPSTEIN; Amit GRUBER; Oded EDRI
- Web page: https://patentgrep.com/patent/US20240002805A1

## CPC

- C12N 5/0657: {Cardiomyocytes; Heart cells}
- A61K 35/34: Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes (vascular smooth muscle A61K35/44)
- A61P 9/06: Antiarrhythmics
- C12N 2502/256: Renal cells
- C12N 2506/45: from artificially induced pluripotent stem cells
- C12N 2510/00: Genetically modified cells
- C12N 2529/10: Stimulation by light
- C12N 2533/90: Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to products and methods for modulating cardiac function.

## Claims

### Claim 1

A method for modulating action potential (AP) properties of cardiac tissue cells of a patient in need thereof, the method comprising the steps of:
(a) providing cardiac tissue cells in which the membrane potential is susceptible to light-dependent modulation, and
(b) illuminating the cardiac tissue cells during the action potential.

### Claim 2 (depends on 1)

The method of claim 1, wherein the method comprises modulating the AP duration (APD) of the cardiac tissue cells.

### Claim 3 (depends on 2)

The method of claim 2, wherein the method comprises elongating the APD of the cardiac tissue cells.

### Claim at position 4

4-41. (canceled)

### Claim 42 (depends on 3)

The method of claim 3, wherein the method comprises improving the contraction of the cardiac tissue cells or silencing the electrical activity of the cardiac tissue cells.

### Claim 43 (depends on 3)

The method of claim 3, wherein the method comprises illuminating the cardiac tissue cells for about 10 to about 2000 milli-seconds, or illuminating at least 50% of the cardiac tissue cells.

### Claim 44 (depends on 2)

The method of claim 2, wherein the method comprises depolarizing the cardiac tissue cells, or illuminating the cardiac tissue cells in phase 2 or phase 3 of the AP.

### Claim 45 (depends on 2)

The method of claim 2, wherein the method comprises shortening the APD of the cardiac tissue cells.

### Claim 46 (depends on 45)

The method of claim 45, wherein the method comprises decreasing the contraction of the cardiac tissue cells or silencing the electrical activity of the cardiac tissue cells.

### Claim 47 (depends on 46)

The method of claim 46, wherein the method comprises illuminating the cardiac tissue cells for about 10 to about 2000 milli-seconds, or illuminating at least 50% of the cardiac tissue cells.

### Claim 48 (depends on 47)

The method of claim 47, wherein the method comprises hyperpolarizing the cardiac tissue cells.

### Claim 49 (depends on 48)

The method of claim 48, wherein the method comprises illuminating the cardiac tissue cells in phase 0, phase 1, phase 2, or phase 3 of the AP.

### Claim 50 (depends on 1)

The method of claim 1, wherein the method comprises changing the slope of repolarization of the AP or extending the plateau phase of the AP.

### Claim 51 (depends on 1)

The method of claim 1 for preventing or treating Short QT Syndrome (SQTS), Long QT Syndrome (LQTS), early-after-depolarizations (EADs) or triggered beats.

### Claim 52 (depends on 1)

The method of claim 1 for preventing or treating cardiac arrhythmia.

### Claim 53 (depends on 52)

The method of claim 52, wherein the arrhythmia is polymorphic ventricular tachycardia, Torsade-de-Pointe (TdP), or reentrant arrhythmia.

### Claim 54 (depends on 1)

The method of claim 1, wherein the patient is afflicted with a Short QT Syndrom (SQTS), Long QT Syndrom (LQTS), cardiac tissue action potential duration (APD) or repolarization heterogeneity.

### Claim 55 (depends on 1)

The method of claim 1, wherein making the membrane potential of the cardiac tissue cells susceptible to light-dependent modulation comprises (a) genetically transforming the cardiac tissue cells with a light-sensitive ion channel, a light-sensitive ion pump, or a light-sensitive signaling receptor, or (b) contacting the cardiac tissue cells with genetically-transformed cells comprising a light-sensitive ion channel, a light-sensitive ion pump, or a light-sensitive signaling receptor.

### Claim 56 (depends on 55)

The method of claim 55, comprising:
(a) expressing a light-sensitive ion channel, a light-sensitive ion pump, or a light-sensitive signaling receptor in the cardiac tissue cells;
(b) contacting the cardiac tissue cells with an oligonucleotide construct encoding a light-sensitive ion channel, a light sensitive ion pump, or a light-sensitive signaling receptor;
(c) administering genetically-transformed cells to the patients' heart, wherein the genetically-transformed cells comprise a light-sensitive ion channel, a light-sensitive ion pump, or a light-sensitive signaling receptor; or
(d) administering genetically-transformed cells to the patients' heart, wherein the genetically-transformed cells comprise an oligonucleotide construct encoding a light-sensitive ion channel, a light-sensitive ion pump, or a light-sensitive signaling receptor.

### Claim 57 (depends on 56)

The method of claim 56 wherein the light-sensitive ion channel, light-sensitive ion pump, or light-sensitive signaling receptor is selected from the group consisting of ChR2, ChR2/H134, ChETA, ChR/T159C, SFO/SSFO, ReaChR, VChR1, Chronos, Chrimson, ChrimsonR, PsChR2, CoChR, CsChR, CheRiff, C1C2, ChIEF, ChEF, ChD, C1V1, iChloC, SwiChRca, GtACR, PsChR1, Phobos, Aurora, Jaws, Halo/NpHR, eNpHR 3.0, Arch, eArch 3.0, ArchT, ArchT 3.0, Mac, and eMac 3.0.
